An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
NCT01277328 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 95
Last updated 2016-09-15
Summary
This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2014-08-31
- Completion
- 2014-08-31
Countries
- Romania
Study Locations
More Related Trials
-
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis
NCT02721004 ·Status: COMPLETED
-
A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis
NCT01462162 ·Status: COMPLETED
-
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01375478 ·Status: COMPLETED
-
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
NCT01543503 ·Status: COMPLETED
-
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01770834 ·Status: COMPLETED
-
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01089023 ·Status: COMPLETED ·Phase: PHASE4
-
A Non-Interventional Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01672970 ·Status: COMPLETED
-
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
NCT00750880 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
NCT02001987 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
NCT01615419 ·Status: COMPLETED
-
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
NCT02011334 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
NCT02046603 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
NCT01283971 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
NCT01214733 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis
NCT01741688 ·Status: COMPLETED
-
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs
NCT01388309 ·Status: COMPLETED
-
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
NCT01663506 ·Status: COMPLETED
-
A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis
NCT01921478 ·Status: COMPLETED
-
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01245439 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
NCT01326962 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
NCT01384461 ·Status: COMPLETED
-
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01670045 ·Status: COMPLETED
-
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
NCT02046616 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
NCT01254331 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
NCT00891020 ·Status: COMPLETED ·Phase: PHASE3